Conference Details



Organizing Committee


Bayhelix China Healthcare Awards

2018 BayHelix China Healthcare Awards

For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. This year, BayHelix and BioCentury jointly hosted the 5th China Healthcare Summit (November 13-14, Shanghai), and presented the awards in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year.

R&D Achievement of the Year

Recognizing a scientific discovery in China with direct impact to drug and/or medtech R&D or a significant achievement in pharmaceutical and/or medtech development milestones.


Hutchison MediPharma – The Innovation Platform of Chi-Med

Fruquintinib, for metastatic colorectal cancer, the first China discovered and developed innovative medicine for a major cancer type to win unconditional approval in China.

Deal of the Year

Recognizing a groundbreaking pharmaceutical and/or medtech fund-raising, collaboration, technology transfer, licensing, M&A or joint venture that involves a Chinese entity, either within China or cross-border.


Zai Lab Ltd./Novocure Ltd.

A groundbreaking strategic partnership that makes Optune, a revolutionary treatment for glioblastoma (GBM), available to patients in Greater China, and helps accelerate the global development of Optune in additional cancers.

Commercial Achievement of the Year

Recognizing a creative model that delivered superior value to patients/payers in China and commercial success.


AstraZeneca plc

Tagrisso’s regulatory approval, reimbursement listing and commercial launch in China all set records in the China pharmaceutical industry.

Company of the Year

Recognizing an outstanding company in China that has made a significant impact on the landscape, reputation and ecosystem of China’s pharmaceutical, medtech and/or healthcare industry.


WuXi AppTec

For its dedication towards building an open-access enabling platform with the most comprehensive capabilities and technologies in the global healthcare industry.  The platform is enabling over 3,000 collaborative partners around the world.

Person of the Year

Recognizing an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem for drug and/or medtech R&D, deal transactions, and/or commercialization etc. in China.


Frank Zhang, Ph.D., CEO, GenScript Biotech Corp.

Frank and his partners have built GenScript from scratch and turned it into a multi-billion dollar company in 16 years. He directed the company into new frontiers like synthetic biology and cell therapy and successfully secured a collaboration and license agreement with J&J/Janssen with a $350M upfront payment, the largest upfront payment so far by a multinational pharma company to a Chinese company.